BioSpace News Archive

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host an Investor Event on December 10 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it intends to offer and sell, subject to market and other conditions American Depositary Shares and warrants to purchase ADSs in an underwritten public offering.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted stock options to purchase an aggregate of 6,100 shares of Karyopharm’s common stock and an aggregate of 4,200 restricted stock units to two newly-hired employees.

Veeva Systems Inc., a leading provider of industry cloud solutions for the global life sciences industry, announced results for its third quarter ended October 31, 2022.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 24,400 shares of TCR2’s common stock to 3 new non-executive employees.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the results of the special meeting of the stockholders held on December 1, 2022.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced that management will participate in the 2022 RBC Capital Markets Healthcare Private Company Virtual Conference.

Allarity Therapeutics, Inc. announced that the Company’s adjourned 2022 Annual Stockholders Meeting set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting will be held, as a virtual meeting, on January 19, 2023.